Document is current
Any future updates will be listed below
-
Authors
Uraki, Ryuta https://orcid.org/0000-0003-0890-1922
Iida, Shun https://orcid.org/0000-0003-2258-9031
Halfmann, Peter J.
Yamayoshi, Seiya https://orcid.org/0000-0001-7768-5157
Hirata, Yuichiro
Iwatsuki-Horimoto, Kiyoko https://orcid.org/0000-0002-8266-020X
Kiso, Maki
Ito, Mutsumi
Furusawa, Yuri
Ueki, Hiroshi https://orcid.org/0000-0002-6557-0771
Sakai-Tagawa, Yuko
Kuroda, Makoto
Maemura, Tadashi
Kim, Taksoo
Mine, Sohtaro
Iwamoto, Noriko
Li, Rong
Liu, Yanan
Larson, Deanna
Fukushi, Shuetsu
Watanabe, Shinji
Maeda, Ken https://orcid.org/0000-0002-3488-5439
Wang, Zhongde https://orcid.org/0000-0003-2441-4729
Ohmagari, Norio
Theiler, James
Fischer, Will https://orcid.org/0000-0003-4579-4062
Korber, Bette https://orcid.org/0000-0002-2026-5757
Imai, Masaki https://orcid.org/0000-0001-6988-1975
Suzuki, Tadaki https://orcid.org/0000-0002-3820-9542
Kawaoka, Yoshihiro https://orcid.org/0000-0001-5061-8296
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP21fk0108615)
Japan Agency for Medical Research and Development (JP22fk0108637)
Japan Agency for Medical Research and Development (JP22wm0125008)
Japan Agency for Medical Research and Development (JP21fk0108552)
Japan Agency for Medical Research and Development (JP22wm0125002)
Japan Agency for Medical Research and Development (JP223fa627001)
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (75N93021C00014)
- License Information
-
More Information
Article History
Received: 2 September 2022
Accepted: 27 February 2023
First Online: 23 March 2023
Competing interests
: Y.K. has received unrelated funding support from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Inc., Shionogi & Co. LTD, Otsuka Pharmaceutical, KM Biologics, Kyoritsu Seiyaku, Shinya Corporation, and Fuji Rebio. The remaining authors declare that they have no competing interests.
